<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450772</url>
  </required_header>
  <id_info>
    <org_study_id>PANC3016</org_study_id>
    <nct_id>NCT03450772</nct_id>
  </id_info>
  <brief_title>Equivalence Study to Compare Two Strengths of Creon in China</brief_title>
  <acronym>CREON</acronym>
  <official_title>Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, randomized, multicenter, cross-over study in 60 subjects with PEI
      delivering data of 60 subjects for Pancreatin Enteric-Coated Capsules 25000 and of 60
      subjects for Pancreatin Enteric-Coated Capsules 10000. The study will be conducted in up to
      10 sites in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of fat absorption</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fat intake - fat excretion/fat intake x 100</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool weight</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptomatology</measure>
    <time_frame>5 days and 24 weeks</time_frame>
    <description>stool frequency, stool consistency, abdominal pain, flatulence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject`s acceptance of treatment and preference</measure>
    <time_frame>5 days and 24 weeks</time_frame>
    <description>Subject's acceptance of treatment will be judged based on the following scale: very good, good, moderate and unsatisfactory.
Which treatment did you prefer? No difference between treatment 1 and treatment 2 Treatment 1 is better than treatment 2 Treatment 2 is better than treatment 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Creon® 25000 then Creon® 10000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic enzyme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon® 10000 then Creon® 25000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic enzyme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon® 25000</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>Creon® 25000 then Creon® 10000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon® 10000</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Creon® 10000 then Creon® 25000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Subjects ≥ 18 years

          -  A) Chronic pancreatitis must be documented in the medical file by at least one of the
             following methods:

               -  Imaging techniques (ultrasound, CT, MRI, or endoscopic ultrasound)

               -  ERCP (endoscopic retrograde cholangiopancreatography)

               -  Plain film of the abdomen with pancreatic calcification or

          -  B) Partial or total pancreatectomy ≥ 30 days prior to enrollment and without current
             postsurgery complications

          -  PEI proven by human fecal elastase ≤ 100 µg/g stool (during the screening period)

          -  Subjects without Creon (Pancreatin Enteric Coated Minimicrospheres) intake in the past
             three months

          -  Females of child-bearing potential should agree to continue using a medically
             acceptable method of birth control throughout the study and for 30 days immediately
             after the last dose of study drug. Medically acceptable methods of birth control
             include bilateral tubal ligation or the use of either a contraceptive implant, a
             contraceptive injection (e.g. Depo-Provera™), an intrauterine device, or an oral
             contraceptive taken within the past three months where the subject agrees to continue
             using during the study or to adopt another birth control method, or a double-barrier
             method which consists of a combination of any two of the following: diaphragm,
             cervical cap, condom, or spermicide

        Exclusion Criteria:

          -  Subjects with a history of fibrosing colonopathy

          -  Solid organ transplant

          -  Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy

          -  Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy

          -  Subjects with recurrent malignant tumors of any kind

          -  Use of an immunosuppressive drug or chemotherapy

          -  Acute phase of pancreatitis

          -  Acute phase of pancreatitis

          -  Subjects who are not able or willing to ingest 90g fat/day (± 10 g fat/day) during the
             cross-over periods or are not willing to collect complete stools during the
             demarcation period.

          -  Subjects in an instable condition after pancreatic surgery (Karnofsky index &lt; 70)

          -  Known infection with HIV

          -  Pregnancy or lactation

          -  Current excessive alcohol intake or drug abuse

          -  Investigational drug intake within prior 30 days

          -  Known allergy against pancreatin of porcine origin or to any of the excipients of
             Pancreatin Enteric-Coated Capsules

          -  Suspected non-compliance or non-cooperation

          -  Celiac disease, Crohn´s disease

          -  Ileus or acute abdomen in the medical history

          -  Mental disability or any other lack of fitness, in the investigator's opinion, to
             preclude subject's participation in or to complete the study

          -  Any acute or chronic disease (i.e infectious diseases) which may limit the
             hospitalization, dietary adherence or stool collection or completion of the study
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suntje Sander, PhD</last_name>
    <phone>+495116750</phone>
    <phone_ext>3254</phone_ext>
    <email>suntje.sander@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhaoshen, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

